Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBTGet Rating) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.50.

A number of research firms have weighed in on CLBT. TheStreet raised shares of Cellebrite DI from a “d+” rating to a “c-” rating in a research note on Friday, February 3rd. Needham & Company LLC reiterated a “buy” rating and set a $6.50 target price on shares of Cellebrite DI in a research report on Thursday, February 16th.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds have recently modified their holdings of the company. Ritholtz Wealth Management bought a new position in Cellebrite DI during the third quarter valued at about $42,000. Greenhaven Road Investment Management L.P. boosted its stake in Cellebrite DI by 53.5% in the 2nd quarter. Greenhaven Road Investment Management L.P. now owns 3,069,869 shares of the company’s stock worth $15,656,000 after purchasing an additional 1,069,869 shares during the period. Crescent Park Management L.P. grew its holdings in Cellebrite DI by 2.5% during the second quarter. Crescent Park Management L.P. now owns 601,537 shares of the company’s stock worth $3,068,000 after purchasing an additional 14,633 shares during the period. Phoenix Holdings Ltd. raised its position in shares of Cellebrite DI by 30.6% in the third quarter. Phoenix Holdings Ltd. now owns 5,952,877 shares of the company’s stock valued at $23,823,000 after buying an additional 1,394,935 shares in the last quarter. Finally, Serengeti Asset Management LP acquired a new position in Cellebrite DI during the third quarter valued at approximately $490,000. 21.66% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Up 1.9 %

Shares of CLBT stock opened at $5.86 on Friday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 9.61, a price-to-earnings-growth ratio of 1.05 and a beta of 1.19. Cellebrite DI has a 12-month low of $3.80 and a 12-month high of $7.69. The firm has a fifty day moving average of $5.05 and a 200-day moving average of $4.71.

Cellebrite DI Company Profile

(Get Rating)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Featured Stories

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.